Antiepileptic drugs are therapies approved to treat patients with epilepsy, a brain disorder in which clusters of nerve cells signal abnormally, which can lead to seizures. These seizures are incidents that occur when group of nerve cells or neurons in brain sends wrong signals. Patients suffering from epilepsy may complain about strange emotions and sensations or they may behave strangely. Epilepsy is the fourth most common brain disorder affecting people of all ages. The causes of epilepsy are undetermined however major risk factors involved include brain injury, brain tumor, stroke, and substance use disorders. For the treatment of epilepsy, antiepileptic medicines (AEDs) are prescribed, preference of the drug depending on the age of the patient, type of seizures to be treated, seriousness of the seizures, and part of the brain involved. Alcoholism, smoking, changing lifestyle and rising geriatric population are the major factor driving the antiepileptic market.
The market for antiepileptic drugs is broadly classified on the basis of first generation antiepileptic drugs and second generation antiepileptic drugs and pipeline drugs. First generation antiepileptic drugs consists of Valproate (Depakote), Oxycarbazepine ((Trileptal), Carbamazepine (Carbatrol), Phenobarbital (Luminal), Primidone (Mysoline), Ethosuximide (Zarontin), Topiramate (Topamax) Phenytoin (Dilantin, Phenytek). Second generation antiepileptic drugs consist of different mechanism of action than the first generation drugs. These consists of Lamotrigine (Lamictal), Pregabalin (Lyrica), Eslicarbazepine acetate Zonisamide (Zonegran), Lacosamide (Vimpat), Levetiracetam (Keppra), (Aptiom/Zebinix), Perampanel (Fycompa), Rufinamide (Banzel/Inovelon), Ezogabine/retigabine (Trobalt/Potiga),. First generation antiepileptic drugs majorly carbamazepine, valproate, phenytoin and oxycarbazepine are dominating the epilepsy therapeutics market. However, second generation AEDs such as levetiracetam, zonisamide and lacosamide are slowly overtaking the antiepileptic drugs market due to its improved tolerability and efficacy.
Request For Sample Report:- http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=7664
The pipeline for antiepileptic drugs has been segmented on different phases. The drugs in the phase III of the pipeline include Brivaracetam (UCB Pharma Ltd), Ganaxolone (Marinus Pharmaceuticals), USL261 (Upsher Smith Laboratories, Inc.), Perampanel (Eisai Co) and YKP3089 (SK Life Sciences) and others. The phase I and II of the pipeline drugs include Buspirone, Everoline, UCB0942 (PPSI), Lacosamide, GWP42006, TAK-932 and others. All this drugs are currently under clinical trials and it is expected that these drugs will prove beneficial for epilepsy therapeutics market.
Geographically, North America dominates the global antiepileptic drugs market followed by Europe majorly due to the extensive research and development activities in the neurology and the presence of pharmaceutical industries in the region. Epilepsy affects approximately 2.5 million people in the United States, and results in an estimated annual cost of approximately $15.5 billion in healthcare. Three new antiepileptic drugs have been approved in U.S. since 2012 including ezogabine/retigabine, perampanel and eslicarbazepine acetate. Continuous increase in uptake of second generation antiepileptic drugs is also driving the antiepileptic drugs market in North America and Europe. Asia-Pacific is also increasing constantly in the antiepileptic drugs market mainly due to the high prevalence of epilepsy in India and China, increased penetration due to better market access options in China and expected approval of drugs with novel mechanisms are some of the factors responsible for expanding the epilepsy therapeutics market in the Asia-Pacific region. Latin America is also a growing market for antiepileptic drugs due to developing healthcare expenditure and high prevalence rate of epilepsy in the region.
Some of the major players in epilepsy therapeutics market include Abbott Laboratories, Cephalon, Inc, GlaxoSmithKline plc,., Johnson & Johnson, Novartis AG, Pfizer, Inc., Sunovion Pharmaceuticals, Inc., Valeant Pharmaceuticals International, Inc., Sanofi S.A. and UCB Pharma Ltd.
This research report analyzes this market on the basis of its market segments, major geographies, and current market trends.
This report provides comprehensive analysis of
- Market growth drivers
- Factors limiting market growth
- Current market trends
- Market structure
- Market projections for upcoming years
Browse Full Report With TOC:- http://www.transparencymarketresearch.com/antiepileptic-drugs-market.html
This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.
Transparency Market Research (TMR) is a next-generation provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.
Transparency Market Research
90 State Street,
Albany NY – 12207